TISSIUM adopted Equify in 2021 to replace an Excel-based cap table that had become unreliable and prone to errors. As the company grew and the number of stakeholders increased, manual management became both risky and time-consuming. The team needed a solution to strengthen data reliability, improve cap table monitoring, and provide greater transparency to investors.
.png)
A KEY TOOL FOR STRENGHTENING THE RELIABILITY OF OUR SHAREHOLDER BASE
In this case study
.png?width=16&height=16&name=fleche-droite%20(6).png){kind=small}
About TISSIUM
About TISSIUM
TISSIUM is a MedTechcompany, based in Paris (France), Cambridge (USA) and with a production facility in Roncq (France), developing a proprietary platform of fully biosynthetic, biomorphic, programmable and elastomeric polymers designed to address unmetclinical needs in atraumatic tissue repair and reconstruction.
TISSIUM's diversified portfolio includes one marketed product and six products in development, across three therapeutic verticals: atraumatic peripheral nerve repair , atraumatic hernia repair and suture line support in cardiovascular surgery. Each solution is designed to optimize tissue repair through controlled, reproducible procedures, using specialized delivery and activation devices to maximize product performance and ergonomics.
Founded in 2013, TISSIUM draws on groundbreaking research and an intellectual property portfolio from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital).
About Romain
About Romain
After starting his career in investment banking, Romain joined TISSIUM in 2021 as Chief Financial Officer. Before joining the company, he spent 11 years in Corporate Finance at ODDO BHF, where he was most recently Managing Director and Head of Public M&A / ECM France. He was involved in numerous market transactions, including IPOs, capital increases, delistings, public offerings and other M&A transactions.
A reliable cap table
A reliable cap table
“With Excel, every change came with a risk of error. Equify helped us move from approximate management to reliable, traceable data.” — Romain, CFO of TISSIUM
Smooth allocation campaigns
Smooth allocation campaigns
Each year, TISSIUM runs BSPCE grant campaigns for its employees. Before Equify, the process was fully manual — document preparation, individual emails, reminders, and signature follow-up. It was long, repetitive, and especially prone to errors. The team spent several weeks on the campaign, repeating the same work year after year, making a more reliable and automated approach essential.
“We transformed a heavy, repetitive annual administrative process into a smooth and secure operation. Each grant is now standardized, traceable, and accessible in just a few clicks, allowing us to manage the entire campaign end to end.” — Romain, CFO of TISSIUM
Beneficiaries now sign documents directly within the platform and can instantly find them in their personal space. With the integrated mailing feature, the annual campaign can be managed in just a few clicks, with complete reliability. Automation delivers two major benefits: stronger legal standardization through a single template for all beneficiaries, and significant time savings for the team.
Instant, reliable data extraction
Instant, reliable data extraction
The ability to generate key outputs in seconds — cap table reports, instruments to be allocated, and the share transfer register — has transformed the team’s day-to-day work. They can now respond immediately to investor reporting requests and close the books using fully reliable information.
"With Equify, we have a single source of truth. Data extraction is instantaneous, enabling us to respond to investors in real time and close our accounts with complete reliability.” — Romain, CFO of TISSIUM
This centralization eliminates re-keying, significantly reduces the risk of errors, and ensures consistent information for all stakeholders. Investor communications are faster, more accurate, and more professional — freeing up time for higher-value work.
The future with Equify
The future with Equify
TISSIUM plans to expand its use of Equify to governance, by managing shareholder meetings directly from the platform. This will centralize the full capital and governance lifecycle in a single tool—from the cap table to equity allocations, and through General Meetings and voting.
“Our goal is to centralize the entire equity lifecycle in Equify, from the cap table to shareholder meetings. Having everything in one place ensures smooth, consistent management.” — Romain, CFO of TISSIUM
This integrated approach will bring even greater efficiency and reliability, simplifying processes and strengthening transparency for all stakeholders.
About TISSIUM
TISSIUM is a MedTechcompany, based in Paris (France), Cambridge (USA) and with a production facility in Roncq (France), developing a proprietary platform of fully biosynthetic, biomorphic, programmable and elastomeric polymers designed to address unmetclinical needs in atraumatic tissue repair and reconstruction.
TISSIUM's diversified portfolio includes one marketed product and six products in development, across three therapeutic verticals: atraumatic peripheral nerve repair , atraumatic hernia repair and suture line support in cardiovascular surgery. Each solution is designed to optimize tissue repair through controlled, reproducible procedures, using specialized delivery and activation devices to maximize product performance and ergonomics.
Founded in 2013, TISSIUM draws on groundbreaking research and an intellectual property portfolio from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital).
About Romain
After starting his career in investment banking, Romain joined TISSIUM in 2021 as Chief Financial Officer. Before joining the company, he spent 11 years in Corporate Finance at ODDO BHF, where he was most recently Managing Director and Head of Public M&A / ECM France. He was involved in numerous market transactions, including IPOs, capital increases, delistings, public offerings and other M&A transactions.
A reliable cap table
TISSIUM adopted Equify in 2021 to replace an Excel-based cap table that had become unreliable and prone to errors. As the company grew and the number of stakeholders increased, manual management became both risky and time-consuming. The team needed a solution to strengthen data reliability, improve cap table monitoring, and provide greater transparency to investors.
“With Excel, every change came with a risk of error. Equify helped us move from approximate management to reliable, traceable data.” — Romain, CFO of TISSIUM
Smooth allocation campaigns
Each year, TISSIUM runs BSPCE grant campaigns for its employees. Before Equify, the process was fully manual — document preparation, individual emails, reminders, and signature follow-up. It was long, repetitive, and especially prone to errors. The team spent several weeks on the campaign, repeating the same work year after year, making a more reliable and automated approach essential.
“We transformed a heavy, repetitive annual administrative process into a smooth and secure operation. Each grant is now standardized, traceable, and accessible in just a few clicks, allowing us to manage the entire campaign end to end.” — Romain, CFO of TISSIUM
Beneficiaries now sign documents directly within the platform and can instantly find them in their personal space. With the integrated mailing feature, the annual campaign can be managed in just a few clicks, with complete reliability. Automation delivers two major benefits: stronger legal standardization through a single template for all beneficiaries, and significant time savings for the team.
Instant, reliable data extraction
The ability to generate key outputs in seconds — cap table reports, instruments to be allocated, and the share transfer register — has transformed the team’s day-to-day work. They can now respond immediately to investor reporting requests and close the books using fully reliable information.
"With Equify, we have a single source of truth. Data extraction is instantaneous, enabling us to respond to investors in real time and close our accounts with complete reliability.” — Romain, CFO of TISSIUM
This centralization eliminates re-keying, significantly reduces the risk of errors, and ensures consistent information for all stakeholders. Investor communications are faster, more accurate, and more professional — freeing up time for higher-value work.
The future with Equify
TISSIUM plans to expand its use of Equify to governance, by managing shareholder meetings directly from the platform. This will centralize the full capital and governance lifecycle in a single tool—from the cap table to equity allocations, and through General Meetings and voting.
“Our goal is to centralize the entire equity lifecycle in Equify, from the cap table to shareholder meetings. Having everything in one place ensures smooth, consistent management.” — Romain, CFO of TISSIUM
This integrated approach will bring even greater efficiency and reliability, simplifying processes and strengthening transparency for all stakeholders.
